Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer
Crossref DOI link: https://doi.org/10.1007/s10637-016-0357-4
Published Online: 2016-05-10
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kattan, Joseph
Bachour, Marwan
Farhat, Fadi
El Rassy, Elie
Assi, Tarek
Ghosn, Marwan
Text and Data Mining valid from 2016-05-10
Version of Record valid from 2016-05-10
Article History
Received: 1 April 2016
Accepted: 5 May 2016
First Online: 10 May 2016
Compliance with ethical standards
:
: None.